Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: BM&FBOVESPA
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

AMGN34:BZ

489.250 BRL 5.350 1.08%

As of 14:33:16 ET on 04/02/2015.

Snapshot for Amgen Inc (AMGN34)

Open: 489.250 Day's Range: 489.250 - 489.250 Volume: 200
Previous Close: 494.600 52wk Range: 246.000 - 529.940 1-Yr Rtn: -

Stock Chart for AMGN34

No chart data available.
  • AMGN34:BZ 489.250
  • 1D
  • 1M
  • 1Y
494.600
Interactive AMGN34 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AMGN34

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. IBOV -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M BRL) 370,372.84
Shares Outstanding (M) 757.02
30 Day Average Volume 33
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 1.99%
Cash Dividend (BRL) 1.6309
Dividend Ex-Date 05/12/2015
5 Year Dividend Growth -
Next Earnings Announcement 04/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AMGN34

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AMGN34

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Robert A Bradway "Bob"Chairman/President/CEOAnnette L SuchChief Accounting Officer
David W MelineExec VP/CFOAnthony C Hooper "Tony"Exec VP:Global Commercial Ops
More Company Profile & Key Executives for AMGN34

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil